

RESEARCH ARTICLE OPEN ACCESS

# Bridging the Gap in Pediatric Relapsed Acute Lymphoblastic Leukemia Treatment: Insights and Outcomes From the ALL-IC REL 2016 Guidelines

Marko Kavcic<sup>1,2</sup>  | Dániel J. Erdélyi<sup>3</sup> | Volkan Hazar<sup>4</sup>  | Mirella Ampatzidou<sup>5</sup>  | Boryana Avramova<sup>6</sup>  | Anca Colita<sup>7</sup>  | Monica Makiya<sup>8</sup> | Sophia Polychronopoulou<sup>5</sup>  | Bence Hóbor<sup>3</sup>  | Tomaz Prelog<sup>1</sup>  | Andrea Reyes<sup>9</sup> | Juan Tordecilla<sup>10</sup> | Koray Yalçın<sup>11</sup>  | Arend von Stackelberg<sup>12</sup> | Janez Jazbec<sup>1,2</sup>

<sup>1</sup>University Children's Hospital, University Medical Centre, Ljubljana, Slovenia | <sup>2</sup>Faculty of Medicine, University of Ljubljana, Vrazov trg, Ljubljana, Slovenia | <sup>3</sup>Semmelweis University, Budapest, Hungary | <sup>4</sup>Memorial Health Group Medstar Yildiz Hospital, Antalya, Turkey | <sup>5</sup>"AGIA SOPHIA" Childrens' Hospital, Athens, Greece | <sup>6</sup>University Hospital "Tzaritza Joanna", Sofia, Bulgaria | <sup>7</sup>Fundeni Clinical Institute, Bucharest, Romania | <sup>8</sup>Hospital Italiano de Buenos Aires, Buenos Aires, Argentina | <sup>9</sup>Hospital Robert de Rio, Santiago, Chile | <sup>10</sup>Clinica Santa Maria, Santiago, Chile | <sup>11</sup>Bahcesehir University Medical Park Goztepe Hospital, Istanbul, Turkey | <sup>12</sup>Charite Berlin, CVK, Berlin, Germany

**Correspondence:** Marko Kavcic ([marko.kavcic@klj.si](mailto:marko.kavcic@klj.si)) | Dániel J. Erdélyi ([erdelyi.daniel@semmelweis.hu](mailto:erdelyi.daniel@semmelweis.hu))

**Received:** 2 April 2025 | **Revised:** 2 September 2025 | **Accepted:** 8 September 2025

**Funding:** This work is supported by DJE: Ministry of Innovation and Technology of Hungary, the National Research, Development and Innovation Fund, Grant No. OTKA K-139139.

**Keywords:** Acute Lymphoblastic Leukemia InterContinental (ALL-IC) | Acute Lymphoblastic Leukemia | relapse

## ABSTRACT

**Background:** The Acute Lymphoblastic Leukemia InterContinental (ALL-IC) Study Group exemplifies the potential of broad international collaboration. Patient outcomes have improved by standardizing therapeutic options and employing flow cytometry-based minimal residual disease (MRD) for treatment stratification. Nevertheless, relapse occurs in 10%–20% of cases, with survival rates falling short of benchmarks set by top-tier published studies.

**Objectives:** We aimed to unify treatment guidelines for children with first relapse of ALL across the ALL-IC network, analyze post-relapse outcomes, and report findings from an observational registry.

**Methods:** Patients were stratified as standard-risk (SR) or high-risk (HR) based on relapse features and genetics. HR criteria included T-cell immunophenotype, very early or early isolated bone marrow relapse, and relapse post-stem cell transplant (SCT). SR was assigned to all others. SCT was indicated in the whole HR group and in SR patients with poor responses (MRD  $\geq$  0.1% on Day 29).

**Results:** Among 370 patients (mean age 9 years; 33.2% female) diagnosed with first relapse between 2017 and 2021, 90.5% had received ALL-IC-Berlin-Frankfurt-Münster (BFM) 2009 treatment initially. Upon relapse, 46.8% were classified as SR and 53.2% as HR. Complete remission rates post-induction were 84% (SR) and 56% (HR). MRD  $<$  0.1% was achieved by 53% (SR) and 29% (HR).

**Abbreviations:** AEs, adverse events; ALL-IC, Acute Lymphoblastic Leukemia InterContinental; BFM, Berlin-Frankfurt-Münster; CNS, central nervous system; EFS, event-free survival; EOI, end-of-induction; FD, family donor; HR, high-risk; ICU, intensive care unit; IntReALL, International Study for the Treatment of Childhood Relapsed ALL; MFD, matched family donor; MMFD, mismatched family donor; MMUD, mismatched unrelated donor; MRD, minimal residual disease; MSD, matched sibling donor; MUD, matched unrelated donor; OS, overall survival; SCT, stem cell transplantation; SR, standard-risk; StE, standard error; TBI, total body irradiation; UD, unrelated donor.

Marko Kavcic and Dániel J. Erdélyi contributed equally as co-first authors.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2025 The Author(s). *Pediatric Blood & Cancer* published by Wiley Periodicals LLC.

Five-year overall survival was 50.5% (74% SR, 32% HR). HR outcomes were hindered by disease progression, treatment toxicity, and posttransplant complications.

**Conclusions:** This inaugural ALL-IC REL Consortium report demonstrates promising SR outcomes, akin to the International Study for the Treatment of Childhood Relapsed ALL (IntReALL) findings, but highlights poor HR outcomes with standard chemotherapy. Novel therapeutic strategies are urgently needed in upcoming ALL-IC-BFM REL protocols.

## 1 | Introduction

Since its inception in 1975, the Berlin-Frankfurt-Münster (BFM) study group (SG) has profoundly reshaped the treatment protocols for Acute Lymphoblastic Leukemia (ALL) [1]. The BFM protocol emerged as a pivotal framework for both pediatric and adult treatment regimens, quickly becoming a bedrock for further advancements in ALL care and significantly improving patient outcomes globally [2–4].

As the International BFM SG entered the new millennium, it broadened the scope of its collaborative efforts with the formation of the ALL InterContinental (IC)-BFM consortium, bringing together experts from 15 countries across three continents [5]. This expansion facilitated greater access to high-caliber clinical trials in regions less represented in such research [6]. However, even with the advancements in primary ALL treatment evidenced by the 2002 and 2009 ALL-IC-BFM trials, relapsed ALL management has remained a significant challenge [5, 6]. This is highlighted by the inconsistent care standards revealed when participating centers were asked to report on relapsed cases following the ALL-IC-BFM 2002 study. Among those with documented protocols, there was a diversity, with more than 20 different treatment regimens reported. Moreover, the 5-year survival rate post-relapse varied widely across the SGs, exhibiting a range from 20% to 63% (unpublished data), underscoring the critical need for standardized approaches in relapsed ALL treatment [7].

In response to these challenges, the ALL-IC REL SG adopted a more accessible strategy, designed to encourage broader participation across its network. This led to the launch of an observational study for relapsed pediatric ALL, utilizing well-established drug combinations and avoiding the complexities of randomization in its initial phase. Such efforts are instrumental in driving forward the standardization of care and gathering data on treatment outcomes [7, 8].

This article navigates the intricate pathways of the proposed strategy, its implications for relapsed ALL patients, and the trajectory toward the standardization of treatment approaches on a global scale. It underlines the collaborative spirit that has driven progress in pediatric oncology and the potential to address pressing scientific inquiries through well-structured investigations [9].

## 2 | Methods

### 2.1 | Study Population

Data were prospectively collected from institutions in countries participating in the ALL-IC-BFM 2002 and 2009 clinical trials

for primary ALL [5, 6]. ALL first relapses that occurred from November 2017 to December 2021 in patients  $\leq 18$  years of age were recruited for analyses.

### 2.2 | Treatment

The treatment guidelines were developed under the guidance of a steering committee consisting of leaders from ALL-IC-BFM institutions and the International Study for the Treatment of Childhood Relapsed ALL (IntReALL) SG and are detailed in the [supplemental material](#). The guidelines employed stratification criteria and treatment elements derived from the IntReALL 2010 study, with a focus on diagnostic and therapeutic means accessible and standardized across the frontline ALL-IC-BFM study participating countries [10]. Patients were stratified into standard-risk (SR) or high-risk (HR) groups based on the immunophenotype of ALL, the relapse site, and the timing of relapse post-initial treatment, following the criteria outlined in the protocols provided as [supplemental materials](#) and as established in the IntReALL 2010 guidelines [11]. Certain genetic subgroups were classified to HR irrespective of other features, and these genetic stratifiers were extended in the September 2019 update version of the protocol—see Appendix 2 in both protocol versions provided as supplementary materials. However, routine testing of some of these genetic variations was very heterogeneous among countries and may also not have been fully reported in the registry, hence the low proportion of certain genetic subgroups highlighted in Table 1.

### 2.3 | Minimal Residual Disease (MRD) Assessment

Treatment efficacy was assessed by measuring MRD using flow cytometry [12]. Centers adhered to a  $\geq 6$ -color flow cytometry protocol for MRD detection, following an amendment to the ALL-IC-BFM 2009 Standard Operating Procedures by M.N. Dworzak and J. Kappelmayer. MRD was measured after the fourth week of induction therapy, where a level of 0.1% or higher indicated a suboptimal response. Patients in the SR group showing suboptimal responses were evaluated for allogeneic stem cell transplantation (SCT). MRD level after induction did not affect further treatment in the HR group, and all patients reaching complete morphological remission were eligible for an SCT after consolidation chemotherapy [10, 13–15].

### 2.4 | Statistical Methods

Event-free survival (EFS) and overall survival (OS) were estimated using the Kaplan–Meier method. The log-rank test

TABLE 1 | Demographic and clinical characteristics of children.

| First presentation, frontline therapy       | SR                            | HR                             |
|---|-------------------------------|--------------------------------|
| N (%)                                       | 173 (46.8)                    | 197 (53.2)                     |
| Sex   |                               |                                |
| Boys  | 124 (71.6)                    | 123 (62.4)                     |
| Girls                                       | 49 (28.3)                     | 74 (37.6)                      |
| Age at primary diagnosis, years             |                               |                                |
| Median (range)                              | 4.3 (0.2–14.6)                | 6.8 (0.3–16.8)                 |
| <10   | 154 (89)                      | 132 (67)                       |
| >10   | 19 (11)                       | 65 (33)                        |
| Primary treatment protocol                  |                               |                                |
| ALL-IC 2009                                 | 154 (89) <sup>a</sup>         | 181 (91.9) <sup>b</sup>        |
| Treatment arm in primary treatment protocol |                               |                                |
| SR  | 40 (23.1)                     | 9 (5.2)                        |
| IR  | 107 (61.8)                    | 105 (53.3)                     |
| HR  | 21 (12.1)                     | 78 (39.6)                      |
| CNS involvement at primary diagnosis (%)    | 7 (4)                         | 17 (8.6)                       |
| <b>Relapse</b>                              |                               |                                |
| Age at relapse (years)                      |                               |                                |
| Median (range)                              | 8 (3.3–17.6)                  | 9 (1–17.99)                    |
| <10   | 118 (68.2)                    | 110 (55.8)                     |
| >10   | 55 (31.8)                     | 87 (44.2)                      |
| Immunophenotype                             |                               |                                |
| B-precursor                                 | 171 (98.8)                    | 153 (77.7)                     |
| T   | 2 (1.2)                       | 43 (21.8)                      |
| MPAL  | 0 (0)                         | 1 (0.5)                        |
| Genetic abnormalities at relapse            |                               |                                |
| Favorable prognosis                         |                               |                                |
| Hyperdiploidy                               | 9 (5.2)                       | 6 (3)                          |
| <i>ETV6::RUNX1</i>                          | 21 (12.1)                     | 4 (2)                          |
| Unfavorable                                 |                               |                                |
| <i>KMT2A</i> rearranged                     | 0                             | 10 (5)                         |
| <i>TCF3::PBX1</i>                           | 3 (1.7)                       | 6 (3)                          |
| Hypodiploidy                                | 0                             | 4 (2)                          |
| BCR::ABL                                    | 0                             | 13 (6.6)                       |
| Other                                       | 6 (3.5) <sup>c</sup>          | 16 (8.1) <sup>d</sup>          |
| Unknown                                     | 134 (77.4)                    | 138 (70.0)                     |
| Extramedullary disease at relapse           |                               |                                |
| CNS   | 36 (CNS2: 3, CNS3: 33) (20.8) | 49 (CNS2: 11, CNS3: 38) (24.9) |

(Continues)

TABLE 1 | (Continued)

| First presentation, frontline therapy                   | SR   | HR  |
|---|--|---|
| Testis  | 42 (24.3)  | 10 (5)  |
| Other   | 8 (maxilla, skin, femur, ovary, fatty tissue, pleura, lymph node, parotid gland, fatty tissue) (3.5) | 6 (breast + BM, palate + right mammary gland + liver + spleen + kidneys, ileum + femur, mediastinum, lymph node, bilateral optic nerve) (3) |
| Time from first diagnosis to relapse, mean (SD), months | 39 (19)  | 16.8 (14.4)   |
| Time from first diagnosis to relapse                    |  |   |
| Very early (<18)  | 0  | 120 (60.9)  |
| Early (≥18 and ≤30)                                     | 39 (22.5)  | 63 (32)   |
| Late (>30)  | 134 (77.5)   | 14 (7.1)  |

Abbreviations: ALL-IC, Acute Lymphoblastic Leukemia InterContinental; CNS, central nervous system; HR, high-risk; IR, intermediate risk; MPAL, mixed phenotype acute leukemia; SR, standard-risk.

<sup>a</sup>Other: 1 pt AEIOP BFM 2009, 6 pts ALL BFM 2002, 2 pts ALL-IC like, 1 pt ALL-BFM 2000, 2 pts NHL-BFM, 5 pts St Jude Total XV.

<sup>b</sup>Other: 5 pts ALL BFM 2002, 4 pts EsphALL, 1 pt I-BFM LBL, 1 pt Infant ALL, 3 pts Interfant, NHL BFM.

<sup>c</sup>Other: 1 pt del(19q), 1 pt p16 deletion, 1 pt RUNX tetrasomy, 1 pt trisomy 11, 1 pt trisomy 7, 1 pt del(9)(p21).

<sup>d</sup>Other: 1 pt ABL1-PDGFRB, 1 pt CDKN2A+ and MYC trisomy, 1 pt 90% CDKN2A gene deletion, 17. Chromosome monosomy, NGS: Tp53, NRAS, NT5C2, 1 pt PAX5del, ETV6del, EBF1del, 1 pt IKZF1 gene 1–8 exon losing ATF7IP-JAK2, 5 pts del(9p21), 1 pt in 20% of cells E2A gene sign was detected, 1 pt 3–4 RUNX1 sign, 1 pt NOTCH1 and NUP124/ABL1 fusion, 1 pt FLT3-ITD, 1 pt SIL-TAL1 fusion, 1 pt t(7:14)(p15;q32).

was used to compare different groups. EFS was defined by the occurrence of a second relapse, death, or secondary malignancy. Probabilities of EFS and OS were calculated from the time of relapse diagnosis to the events defined above or any cause of death, respectively. Patients lost to follow-up were censored at the last known contact.

### 3 | Results

#### 3.1 | Total Cohort

Out of the initial 772 patients registered in the electronic registry, 457 were diagnosed with a relapse between November 2017 and December 2021. A total of 87 records were excluded from the final analyses as detailed in Figure 1. The remaining 370 patients comprised the final cohort for analysis. Table 1 delineates the demographics and clinical characteristics of these patients, stratified by their assigned risk group for relapse. These patients were




FIGURE 1 | Flowchart of patient selection.

treated across several countries [8] participating in the ALL-IC-BFM study. Not all full-member groups of the frontline ALL-IC trials participated in this project or filled the registry. On the other hand, some observer countries did participate. Argentina (only the GATLA group,  $N = 111$ ), Bulgaria ( $N = 13$ ), Chile ( $N = 71$ ), Greece ( $N = 7$ ), Hungary ( $N = 25$ ), Romania ( $N = 16$ ), Slovenia ( $N = 7$ ), and Turkey ( $N = 120$ ) registered cases, and hence contributed to the analyses being presented. The ALL-IC REL Guidelines have also been used in Armenia, Bosnia–Herzegovina, Croatia, Georgia, Lebanon, Montenegro, Russia, Serbia, and Ukraine to our knowledge, though these countries contributed with no or with less than three cases each to the registry.

Different protocol was defined as any different induction cycle used. Patients with later deviations from the protocol were not excluded.

### 3.2 | Outcomes: EFS, OS, MRD Remission, and Allogeneic Hematopoietic SCT Outcomes

Table 2 illustrates the outcomes concerning EFS, OS, MRD, remission, and post-allogeneic hematopoietic SCT. Events occurred in 34.1% (59 of 173) of SR patients and 72.6% (143 of 197) of HR patients. The Kaplan–Meier analysis estimated 5-year EFS and OS rates for the cohort at 44.3% and 50.5%, respectively, with Figures 2–4 depicting these outcomes segregated by risk stratification. In the full cohort, six patients who relapsed had been treated for infant ALL on frontline therapy. The only patient in the SR group was alive at last follow-up, whereas one of five HR patients survived.

### 3.3 | Stratification and Outcomes Based on MRD

After induction, 58.2% of SR patients achieved MRD levels  $< 0.1\%$ . These patients had a 5-year EFS of  $63.8\% \pm 5.2\%$ , which was only slightly higher than the  $60.9\% \pm 6.1\%$  seen in patients with MRD  $\geq 0.1\%$  ( $p = 0.27$ ). A similar pattern was seen for OS: SR patients with MRD  $< 0.1\%$  had a 5-year OS of  $74.6\% \pm 4.8\%$  versus  $68.7\% \pm 5.8\%$  for those with MRD  $\geq 0.1\%$  ( $p = 0.27$ ) (Figure 3).

TABLE 2 | Event-free survival, overall survival, minimal residual disease remission, and allogeneic hematopoietic stem cell transplant outcomes.

|   | SR ( $N = 173$ )     | HR ( $N = 197$ )     |
|---|----------------------|----------------------|
| <b>Primary end points</b>   |                      |                      |
| Median follow-up of total cohort (years)  | 4.36 (IQR 2.79–5.54) | 0.86 (IQR 0.37–3.62) |
| Median follow-up of patients alive at last follow-up (years)  | 4.97 (IQR 4.1–6)     | 4.3 (IQR 3.7–5.7)    |
| 5 years event-free survival (StE)   | 64.5 ( $\pm 3.7$ )   | 26.9 ( $\pm 3.2$ )   |
| 5 years Overall survival (StE)  | 74 ( $\pm 3.5$ )     | 32 ( $\pm 3.4$ )     |
| Events (subsequent relapse or death)  | 59 (34.1)            | 143 (72.6)           |
| EOI complete remission (M1)   | 137/162 (84.6)       | 107/175 (61.1)       |
| EOI flow MRD $< 0.1\%$  | 92/158 (58.2)        | 58/163 (35.6)        |
| Event after achievement of complete remission   | 42/137 (30.7)        | 65/111 (58.6)        |
| Event after EOI MRD $< 0.1$   | 32/92 (34.8)         | 34/58 (58.6)         |
| Total second relapses   | 43 (24.9)            | 75 (38)              |
| Death from any cause other than relapse   | 27/44 (61.4)         | 54/134 (40.3)        |
| Second malignancy   | 0                    | 0                    |
| <b>Secondary end points</b>   |                      |                      |
| Death from any cause  | 44 (25.4)            | 134 (68)             |
| Death during induction  | 1 (2.3)              | 11 (8.2)             |
| Death after EOI CR  | 36 (81.8)            | 60 (44.8)            |
| Death after EOI MRD $< 0.1\%$   | 24 (54.5)            | 32 (23.9)            |
| Subset of patients who underwent allogeneic hematopoietic stem cell transplant in second complete remission | 75 (43.4)            | 92 (46.7)            |
| Time to transplant, median (range), months  | 7.2 (3.2–31.3)       | 5.3 (0.8–28)         |
| Donor type  |                      |                      |
| MSD/MFD   | 23/5                 | 24/5                 |
| MUD   | 29                   | 35                   |
| MMFD/MMUD   | 6/1                  | 16/1                 |
| FD/UD—unknown HLA typing  | 4/4                  | 3/6                  |
| Conditioning: TBI based   | 51                   | 54                   |
| Conditioning: Chemotherapy based  | 14                   | 29                   |

(Continues)

TABLE 2 | (Continued)

|   | SR (N = 173) | HR (N = 197) |
|---|--------------|--------------|
| Died after receiving a hematopoietic stem cell transplant | 21/75 (28)   | 40/92 (43.5) |
| Transplant-related death                                  | 9            | 12           |
| Died due to relapse/disease progression after SCT         | 6            | 19           |

Abbreviations: EOI, end-of-induction; FD, family donor; MFD, matched family donor; MMFD, mismatched family donor; MMUD, mismatched unrelated donor; MRD, minimal residual disease; MSD, matched sibling donor; MUD, matched unrelated donor; SCT, stem cell transplant; StE standard error; TBI, total body irradiation; UD, unrelated donor.

Despite recommendations for further chemotherapy, 20 patients with MRD < 0.1% underwent SCT. These standard-risk patients, who received SCT despite favorable MRD levels, had estimated 5-year EFS and OS rates of 54% ± 11.4% and 61.1% ± 11.9%, respectively ( $p = 0.24$  and  $0.17$ ). Among these SR patients, seven deaths occurred—three were relapse-related, two were treatment-related, and two were attributable to the transplant. In the SR cohort with favorable MRD who did not undergo transplantation ( $n = 72$ ), 15 deaths were recorded: nine were relapse-related, four were treatment-related, and two lacked a recorded cause. MRD data were available for 157 of 173 SR patients (91.3%).

In the HR cohort, 58 of 163 patients (35.6%) achieved MRD < 0.1% after induction therapy. Their 5-year EFS was 40.2% ± 6.5%, compared with 23.2% ± 4.2% in patients with higher MRD levels. HR patients who underwent SCT had estimated 5-year EFS and OS rates of 49.1% ± 5.3% and 54.6% ± 5.4%, respectively. In contrast, HR patients who did not receive SCT ( $n = 105$ ) had poor outcomes: 5-year EFS was 7.2% ± 2.6% ( $p < 0.001$ ) and OS 10.0% ± 3.0% ( $p < 0.001$ ). Among these non-transplanted HR patients, 94 deaths were recorded: 62 were relapse-related, 30 were treatment-related, and 2 lacked a recorded cause (Figure 4).

A subgroup of 43 patients with T-cell immunophenotype was treated on the HR arm. MRD levels were measured in 33 of these patients, and 15 achieved end-of-induction MRD < 0.1%. Thirteen of the 15 underwent SCT, with estimated 5-year EFS and OS of 40.0% ± 12.6% and 43.8% ± 12.4%, respectively (Figure 5).

### 3.4 | MRD Dynamics and the Use of Immunotherapy

For patients with high initial MRD, subsets in both SR and HR groups achieved MRD levels of less than 0.1% following additional treatment. Specifically, of the 66 SR patients with end-of-induction (EOI) MRD greater than or equal to 0.1%, 29 attained MRD levels below 0.1% before the SC3 block. Similarly, among the 135 HR patients with high EOI MRD (>0.1%), 29 successfully reduced their MRD to below 0.1% prior to undergoing SCT.

Of the patients with high EOI MRD, 29 were treated with blinatumomab, and their survival outcomes varied by risk category

as follows. In the SR group, 8 out of 11 patients survived the follow-up period. In contrast, in the HR group, 6 out of 18 patients survived. Inotuzumab was administered to six patients—five in the HR group and one in the SR group—with one HR patient surviving and being censored at the time of SCT. All 13 patients with Ph+ ALL in this cohort received a tyrosine kinase inhibitor (TKI) during relapse therapy and were assigned to the HR arm.

Overall, SCT was conducted in 43.4% of SR and 46.7% of HR patients. Among HR patients who did not proceed to transplant, the most common reasons included refractory or progressive disease ( $N = 55$ ) and treatment-related mortality ( $N = 20$ ). In a minority of cases, noncompliance or donor and logistical limitations ( $N = 10$ ) were contributing factors, or the reason for not transplanting was not reported.

### 3.5 | Adverse Events (AEs)

AEs were systematically recorded from the start of therapy to SCT or the end of the final consolidation chemotherapy cycle (SC7) for the SR group. Table 3 compiles these events, revealing a range of AEs with varying frequencies and severities across the chemotherapy courses. Infections were the most common AEs, markedly affecting mortality, especially during the induction phase, with moderate-to-severe infections reported in 60% of the SR group and 79% of the HR group. The HR group also encountered a higher frequency of intensive care unit (ICU) admissions and severe AEs, underlining the increased management challenges associated with their treatment toxicity.


## 4 | Discussion

The prognosis for children with ALL has improved significantly, yet relapse remains a significant cause of mortality [9]. The ALL-IC-BFM consortium, through its international cooperative efforts, has enabled the recruitment of a sufficient number of patients to conduct meaningful clinical studies, a necessity given the disease's rarity [5, 6].

Our initiative aimed to standardize diagnostic and treatment guidelines for children with the first relapse of ALL, focusing on institutions not engaged in prospective randomized trials. This report represents the first consolidated outcome data from the consortium, highlighting the feasibility of intensive chemotherapy across participating middle-income countries.


In the SR group, the observed toxicity was within acceptable limits, and the EFS and OS rates were comparable to contemporary control arms of clinical trials, signaling an encouraging trend [13], for example, with preliminary findings from the IntReALL SR 2010 cohort, reported in abstract form that demonstrated favorable outcomes with the ALL-REZ BFM 2002 regimen, particularly in patients with isolated central nervous system (CNS) relapse [16]. Given the relatively favorable prognosis and distinct biology of isolated extramedullary relapses, particularly in the SR group, this subgroup represents an important focus for future analysis, and a dedicated study in our expanded cohort is currently in preparation.

A. Event-free survival



|               | 0 year | 1 year | 2 years | 3 years | 4 years | 5 years |
|---------------|--------|--------|---------|---------|---------|---------|
| SR, N at risk | 173    | 153    | 129     | 113     | 90      | 57      |
| HR, N at risk | 197    | 77     | 53      | 50      | 40      | 19      |

B. Overall survival




|               | 0 year | 1 year | 2 years | 3 years | 4 years | 5 years |
|---------------|--------|--------|---------|---------|---------|---------|
| SR, N at risk | 173    | 159    | 144     | 129     | 106     | 64      |
| HR, N at risk | 197    | 91     | 68      | 59      | 46      | 22      |


**FIGURE 2** | Event-free survival and overall survival by risk group. (A) Event-free survival. (B) Overall survival. HR, high-risk; SR, standard-risk.

HR patients presented with a less favorable prognosis, with OS probabilities below 30%. Despite various conventional cytotoxic drug combinations used in past trials, outcomes have not surpassed the 50% threshold, even with allogeneic SCT. The non-blinatumomab arm of the IntReALL 2010 HR study yielded a similar EFS to ours; however, it had better

OS (49% at 4 years). Our results underscore the urgent need for integrating novel therapeutic agents alongside systemic therapy for HR patients, as evidenced by recent phase-3 studies highlighting the efficacy of blinatumomab [17, 18] and also implementing immunotherapies at further relapses.




|                                | 0 year | 1 year | 2 years | 3 years | 4 years | 5 years |
|--------------------------------|--------|--------|---------|---------|---------|---------|
| EOI MRD < 0.1%, N at risk      | 58     | 36     | 28      | 24      | 21      | 10      |
| EOI MRD > or = 0.1%, N at risk | 105    | 41     | 29      | 27      | 18      | 7       |




|                                | 0 year | 1 year | 2 years | 3 years | 4 years | 5 years |
|--------------------------------|--------|--------|---------|---------|---------|---------|
| EOI MRD < 0.1%, N at risk      | 92     | 88     | 83      | 70      | 59      | 38      |
| EOI MRD > or = 0.1%, N at risk | 65     | 58     | 50      | 45      | 36      | 19      |

**FIGURE 3** | Overall survival according to end-of-induction (EOI) flow MRD result. MRD, minimal residual disease.




**FIGURE 4** | Overall survival in (A) high-risk and (B) standard-risk patients with and without stem cell transplant (SCT).

A. Overall survival in high-risk patients stratified according to the immunophenotype



|                  | 0 year | 1 year | 2 years | 3 years | 4 years | 5 years |
|------------------|--------|--------|---------|---------|---------|---------|
| B-ALL, N at risk | 153    | 73     | 53      | 46      | 35      | 16      |
| T-ALL, N at risk | 43     | 15     | 12      | 11      | 9       | 4       |

B. Overall survival of patients with T-ALL according to end-of-induction (EOI) flow MRD result



|                                | 0 year | 1 year | 2 years | 3 years | 4 years | 5 years |
|--------------------------------|--------|--------|---------|---------|---------|---------|
| EOI MRD < 0.1%, N at risk      | 15     | 8      | 6       | 6       | 6       | 3       |
| EOI MRD > or = 0.1%, N at risk | 18     | 6      | 5       | 4       | 2       | 1       |

**FIGURE 5** | (A) Overall survival in high-risk patients stratified according to the immunophenotype. (B) Overall survival of patients with T-ALL according to end-of-induction (EOI) flow MRD result. ALL, Acute Lymphoblastic Leukemia; MRD, minimal residual disease.

**TABLE 3** | Frequency and severity of adverse events by chemotherapy course in standard-risk (SR) and high-risk (HR) groups.

| Chemotherapy cycle                                  | SR (N = 162) |     |     |     |     |     |     | HR (N = 171) |              |      |     |     |     |              |
|---|--------------|-----|-----|-----|-----|-----|-----|--------------|--------------|------|-----|-----|-----|--------------|
|   | SI           | SC1 | SC2 | SC3 | SC4 | SC5 | SC6 | SC7          | Total events | HI   | HC1 | HC2 | HC3 | Total events |
| Toxicity data available                             | 161          | 145 | 143 | 135 | 109 | 98  | 88  | 84           | 962          | 169  | 139 | 123 | 109 | 540          |
| ICU admission                                       | 12           | 4   | 2   | 2   | 0   | 1   | 0   | 2            | 23           | 41   | 17  | 14  | 3   | 75           |
| Infection   |              |     |     |     |     |     |     |              |              |      |     |     |     |              |
| Moderate: no organism isolated; on i.v. antibiotics | 63           | 46  | 37  | 29  | 18  | 20  | 15  | 12           | 240          | 53   | 62  | 57  | 34  | 206          |
| Severe (organism isolated)                          | 24           | 9   | 4   | 8   | 7   | 7   | 3   | 3            | 65           | 52   | 31  | 19  | 16  | 118          |
| Life-threatening with hypotension                   | 9            | 1   | 1   | 0   | 0   | 2   | 0   | 0            | 13           | 19   | 5   | 10  | 2   | 36           |
| Cause of death                                      | 2            | 0   | 0   | 2   | 0   | 0   | 0   | 0            | 4            | 11   | 5   | 5   | 0   | 21           |
| Thrombosis  | 6            | 4   | 1   | 2   | 0   | 1   | 1   | 0            | 15           | 10   | 6   | 4   | 2   | 22           |
| Pancreatitis  | 2            | 2   | 0   | 0   | 2   | 1   | 0   | 0            | 7            | 3    | 1   | 0   | 0   | 4            |
| Steroid diabetes                                    | 11           | 5   | 2   | 6   | 3   | 3   | 2   | 5            | 37           | 7    | 0   | 3   | 0   | 10           |
| Stomatitis  | 30           | 24  | 9   | 18  | 8   | 12  | 9   | 10           | 120          | 81   | 54  | 36  | 31  | 202          |
| PNS/CNS toxicity > gr 2                             | 2/5          | 3/8 | 1/5 | 5/4 | 8/3 | 2/4 | 3/2 | 1/2          | 25/33        | 9/12 | 5/7 | 5/6 | 3/4 | 22/29        |
| Diarrhea (also at night, mild cramping)             | 4            | 2   | 2   | 5   | 1   | 0   | 3   | 1            | 18           | 24   | 11  | 11  | 4   | 50           |
| Major protocol deviation due to AE reported         | 4            | 7   | 1   | 2   | 3   | 2   | 3   | 1            | 23           | 14   | 3   | 3   | 3   | 23           |

Abbreviations: AE, adverse event; CNS, central nervous system; HC, high-risk consolidation; HI, high-risk induction; ICU, intensive care unit; PNS, peripheral nervous system; SC, standard-risk consolidation; SI, standard-risk Induction.

Flow cytometry has been instrumental in MRD quantification, aligning closely with molecular genetic approaches in prognostic value [13, 19]. For SR patients, achieving an EOI MRD of less than 0.1% correlated with satisfactory OS rates without SCT. Conversely, for those with an EOI MRD above 0.1%, successful SCT appeared to mitigate the suboptimal response to initial chemotherapy, echoing findings from Eckert et al. [10, 14]. Of note, SR patients with good EOI MRD transplanted against protocol advice tended to have poorer outcomes than patients treated with consolidation chemotherapy without SCT.

The HR group's challenges are underlined by their lower response rates to induction therapy and high relapse rates post-SCT. Notably, only a small fraction of HR patients with high initial EOI MRD levels achieved satisfactory reduction before SCT. This indicates that our current chemotherapy treatments might be insufficient, necessitating the inclusion of new therapeutic strategies for both SR and HR groups with high initial EOI MRD levels. The significant barrier here is the prohibitive cost of immunotherapy, which is not uniformly accessible across the consortium's participant countries.

Although our findings offer valuable insights into the treatment of relapsed ALL in children, there are inherent limitations to our approach that merit consideration. The variability in healthcare infrastructure and resources among the participating ALL-IC REL countries may affect diagnostic capabilities, the implementation of the standardized treatment guidelines, and subsequent outcome reporting [5, 6]. This variability could influence the generalizability of our results. Furthermore, the observational nature of our registry trial—without randomization and control groups—constrains our capacity to make causal inferences about the effectiveness of the treatment strategies. The reliance on flow cytometry for MRD stratification, albeit effective, may not be consistent across the consortium, potentially leading to variability in prognostic accuracy. Economic limitations within the consortium may have also hindered access to newer therapies, for example, haploidentical SCT or total body irradiation (TBI) or targeted therapies, disproportionately impacting the HR group's outcomes. These factors necessitate a careful interpretation of the results and substantiate the imperative for ongoing efforts to validate and enhance these benchmark outcomes.

Our comparative data lay the groundwork for benchmarking outcomes in children with primary ALL relapse in high-intermediate income countries. They corroborate prior findings on the poor prognosis associated with specific patient subsets and validate the feasibility of modern intensive chemotherapy across diverse medical infrastructures. As the field of precision medicine and immunotherapy evolves, we plan to refine our registry to accommodate various treatment pathways, enhancing our guidelines to continually improve patient outcomes globally.

## Ethics Statement

Ethical approval for the study was obtained from the local medical research ethics committees.

## Consent

Informed consent was secured from the patients or their guardians, in line with the prevailing local regulations.

## Conflicts of Interest

The authors declare no conflicts of interest.

## Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## References

1. A. Mörücke, M. Zimmermann, A. Reiter, et al., "Long-Term Results of Five Consecutive Trials in Childhood Acute Lymphoblastic Leukemia Performed by the ALL-BFM Study Group From 1981 to 2000," *Leukemia* 24, no. 2 (2010): 265–284.
2. M. Schrappe, A. Reiter, W. D. Ludwig, et al., "Improved Outcome in Childhood Acute Lymphoblastic Leukemia Despite Reduced Use of Anthracyclines and Cranial Radiotherapy: Results of Trial ALL-BFM 90," *Blood* 95, no. 11 (2000): 3310–3322.
3. J. R. Kowalczyk, J. Zawitkowska, M. Lejman, et al., "Long-term Treatment Results of Polish Pediatric and Adolescent Patients Enrolled in the ALL IC-BFM 2002 Trial," *American Journal of Hematology* 94, no. 11 (2019): E307–E310.
4. U. K. Nath, D. Chattopadhyay, A. Bakliwal, S. Vaniyath, R. Chetia, and A. K. Rajoreya, "Encouraging Results With All IC-BFM 2009 Protocol Therapy in Pediatric Acute Lymphoblastic Leukemia/Lymphoma in Resource-Limited Setting: A Single-Center Study From India," *Blood* 134 (2019): 5118–5118.
5. J. Sary, M. Zimmermann, M. Campbell, et al., "Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002," *Journal of Clinical Oncology off American Journal of Clinical Oncology* 32, no. 3 (2014): 174–184.
6. M. Campbell, C. Kiss, M. Zimmermann, et al., "Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial," *Journal of Clinical Oncology off American Journal of Clinical Oncology* 41, no. 19 (2023): 3499–3511.
7. S. Buchmann, M. Schrappe, A. Baruchel, et al., "Remission, Treatment Failure, and Relapse in Pediatric ALL: An International Consensus of the Ponte-di-Legno Consortium," *Blood* 139, no. 12 (2022): 1785–1793.
8. S. P. Hunger and E. A. Raetz, "How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population," *Blood* 136, no. 16 (2020): 1803–1812.
9. C. H. Pui, J. J. Yang, S. P. Hunger, et al., "Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration," *Journal of Clinical Oncology off American Journal of Clinical Oncology* 33, no. 27 (2015): 2938–2948.
10. C. Eckert, G. Henze, K. Seeger, et al., "Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group," *Journal of Clinical Oncology off American Journal of Clinical Oncology* 31, no. 21 (2013): 2736–2742.
11. G. Tallen, R. Ratei, G. Mann, et al., "Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90," *Journal of Clinical Oncology off American Journal of Clinical Oncology* 28, no. 14 (2010): 2339–2347.

12. M. Maurer-Granofszky, A. Schumich, B. Buldini, et al., “An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report,” *Cancers* 13, no. 23 (2021): 6148.
13. C. Eckert, S. Groeneveld-Krentz, R. Kirschner-Schwabe, N. Hagedorn, C. Chen-Santel, and P. Bader, “Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics,” *Journal of Clinical Oncology off American Journal of Clinical Oncology* 37, no. 36 (2019): 3493–3506.
14. C. Eckert, A. von Stackelberg, K. Seeger, et al., “Minimal Residual Disease After Induction Is the Strongest Predictor of Prognosis in Intermediate Risk Relapsed Acute Lymphoblastic Leukaemia—Long-Term Results of Trial ALL-REZ BFM P95/96,” *European Journal of Cancer (Oxford, England: 1990)* 49, no. 6 (2013): 1346–1355.
15. P. Bader, H. Kreyenberg, G. H. R. Henze, et al., “Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group,” *Journal of Clinical Oncology off American Journal of Clinical Oncology* 27, no. 3 (2009): 377–384.
16. A. von Stackelberg, J. P. Bourquin, M. Zimmermann, et al., “ALL-REZ BFM 2002 Is Associated With Improved Outcome as Compared to ALL-R3 Strategy in Children With Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, While Maintaining Comparable Efficacy in Patients With Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010,” *Blood* 140, no. S1 (2022): 3247–3249.
17. F. Locatelli, G. Zugmaier, C. Rizzari, et al., “Effect of Blinatumomab vs Chemotherapy on Event-Free Survival among Children With High-Risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial,” *JAMA* 325, no. 9 (2021): 843–854.
18. P. A. Brown, L. Ji, X. Xu, et al., “Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults with First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial,” *JAMA* 325, no. 9 (2021): 833–842.
19. C. Eckert, C. Parker, A. V. Moorman, et al., “Risk Factors and Outcomes in Children With High-Risk B-Cell Precursor and T-Cell Relapsed Acute Lymphoblastic Leukaemia: Combined Analysis of ALLR3 and ALL-REZ BFM 2002 Clinical Trials,” *European Journal of Cancer (Oxford, England: 1990)* 151 (2021): 175–189.

### Supporting Information

Additional supporting information can be found online in the Supporting Information section.

**Supporting File 1:** pbc32063-sup-0001-SuppMat.pdf **Supporting File 2:** pbc32063-sup-0002-SuppMat.pdf